ArticleMacromolecular bioscience2026
Animal-Free Derived Collagen-Like Protein Based Electrospun Nanofibers for Biomedical Applications: Cell Interactions Studies.
Article in Macromolecular bioscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Biocompatibility of biomaterials is essential for their application in the biomedical field, particularly in tissue engineering and drug delivery systems. This study focuses on VECOLLAN, a recombinant, non-animal-derived collagen-like protein (CLP), which exhibits excellent biocompatibility while promoting in vitro cell proliferation and wound healing. We previously optimized electrospinning parameters and employed a coaxial crosslinking approach to produce VECOLLAN-based fibers with tunable dissolution, swelling behavior, and elasticity suitable for biomedical applications. The current study aims to assess the compatibility of these fibers with cells (NIH/3T3), investigate chemical leachables from three different formulations of DMTMM cross-linked VECOLLAN-fibers (according to ISO 10993-18), and conduct spectroscopic analysis to confirm crosslinking efficacy. Results indicate that most CLP-based nonwoven mats maintained cell viability above the 70% safety threshold as per ISO-10993-5. The sample with a CLP:DMTMM ratio of 1:0.1 demonstrated the most favorable cell compatibility and effective crosslinking. While the coaxial crosslinking method showed efficiency, residual crosslinker molecules and unexpected derivatives are identified. Spectroscopic investigations gave hints of successful crosslinking, although a direct correlation between crosslinker concentration and spectral band intensity is not established. Future research shall explore additional crosslinkers and cell types to further investigate the biocompatibility and potential applications of VECOLLAN-based nonwoven mats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.